Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business

通过增加 BioLife 具有差异化、高利润率的经常性收入业务，加速 Repligen 在高增长的细胞治疗市场中的领导地位和客户解决方案供应。

BioLife stockholders to receive cash and Repligen common stock at a value of $31.00 per share, representing a total enterprise value of approximately $1.5 billion

BioLife 股东将获得现金及 Repligen 普通股，每股价值为 31.00 美元，代表总企业价值约为 15 亿美元

Compelling financially, the transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two

从财务角度来看，该交易具有吸引力，预计将在第一年使Repligen的营收增长、调整后利润率和调整后每股收益至少增加5美分，在第二年至少增加25美分。

Repligen reports preliminary second quarter reported revenue growth of approximately 12% or 13% organic; BioLife reports preliminary second quarter revenue growth of approximately 21% year-over-year

Repligen报告第二季度初步营收增长约为12%或13%（有机增长）；BioLife报告第二季度初步营收同比增长约21%

WALTHAM, Mass. and BOTHELL, Wash., July 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen,” or “the Company”), a life sciences company focused on bioprocessing technology leadership, and BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, today announced they have entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total enterprise value of approximately $1.5 billion, comprised of 64% in Repligen common stock and 36% in cash (the “Transaction”).

马萨诸塞州沃尔瑟姆和华盛顿州博塞尔，2026年7月22日（环球电讯社）——专注于生物工艺技术领先地位的生命科学公司Repligen Corporation（纳斯达克股票代码：RGEN，“Repligen”或“公司”）与细胞和基因疗法（“CGT”）市场领先的细胞处理工具和服务开发商及供应商BioLife Solutions, Inc.（纳斯达克股票代码：BLFS，“BioLife”）今日宣布，双方已签订一项最终协议，根据该协议，在满足惯例交割条件的前提下，Repligen将以约15亿美元的总企业价值收购BioLife，对价包括64%的Repligen普通股和36%的现金（以下简称“本次交易”）。

The directors of each company unanimously approved the Transaction..

各公司的董事一致批准了该交易。

Olivier Loeillot, President and Chief Executive Officer of Repligen, said: “The acquisition of BioLife represents a natural next step in the evolution of our strategy and further strengthens our position as a leading provider of mission-critical technologies for biologics manufacturing. BioLife brings a highly differentiated portfolio of products including a market-leading biopreservation media platform and other cell processing tools.

Repligen公司总裁兼首席执行官Olivier Loeillot表示：“收购BioLife是我们战略演进的自然下一步，进一步巩固了我们作为生物制药制造关键任务技术领先提供商的地位。BioLife带来了一系列高度差异化的产品组合，包括市场领先的生物保存培养基平台以及其他细胞处理工具。”

This opportunity will expand Repligen’s presence in the rapidly growing cell therapy market, broaden our solutions offering to cell therapy customers, and add a deeply embedded, high-margin consumables business with attractive recurring revenue. Just as important, we believe our shared culture of innovation and customer centricity will create a strong foundation for future growth and value creation.”.

此次机遇将扩大Repligen在快速增长的细胞治疗市场中的影响力，拓宽我们面向细胞治疗客户的产品解决方案组合，并增加一项深度嵌入、高利润率的耗材业务，带来可观的持续性收入。同样重要的是，我们相信双方共同秉持的创新文化和以客户为中心的理念，将为未来的增长和价值创造奠定坚实基础。

“Over the past several years, we have successfully repositioned BioLife around our market-leading biopreservation media franchise, while strengthening our financial profile and establishing a durable foundation for profitable growth,” said Roderick de Greef, Chairman and Chief Executive Officer of BioLife.

“在过去几年中，我们围绕市场领先的生物保存培养基业务成功重塑了BioLife的市场定位，同时强化了我们的财务状况，为盈利性增长奠定了坚实基础。”BioLife董事长兼首席执行官罗德里克·德·格里夫表示。

“Repligen shares our commitment to providing innovative, differentiated, and enabling tools that help customers bring important therapies to patients. Its global commercial reach, complementary technologies and proven operating capabilities make Repligen an ideal partner for BioLife. This Transaction will expand the reach and impact of our portfolio, while providing BioLife stockholders with immediate cash value and the opportunity to participate in Repligen’s future growth.”.

“Repligen 与我们一样，致力于提供创新、差异化且具备赋能作用的工具，帮助客户将重要的疗法带给患者。其全球商业覆盖范围、互补的技术以及经证实的运营能力，使 Repligen 成为 BioLife 的理想合作伙伴。本次交易将扩大我们产品组合的覆盖范围和影响力，同时为 BioLife 股东提供即时现金价值，并使其有机会参与 Repligen 未来的增长。”

Compelling Strategic and Financial Rationale

令人信服的战略与财务理由

Cell therapy represents a significant and growing portion of the global pharma pipeline, while commercial revenues are projected to grow at more than 20% annually through the end of the decade. BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen's existing offering in this market.

细胞疗法在全球制药研发管线中占据重要且日益增长的份额，而商业收入预计将在本十年末之前以每年超过20%的速度增长。BioLife的产品深深嵌入细胞疗法的工作流程中，并与Repligen在该市场的现有产品高度互补。

BioLife’s differentiated biopreservation media portfolio, led by CryoStor®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships..

BioLife 以 CryoStor® 为主导的差异化生物保存培养基产品组合，支持了 18 种已获商业批准的疗法以及美国大多数由企业赞助的细胞治疗临床试验。作为一支联合商业团队，BioLife 将受益于 Repligen 更广泛的全球覆盖范围（包括亚太地区），而 Repligen 则将受益于 BioLife 与客户之间建立的信任关系。

The Transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two. Repligen expects at least $20 million of synergies in year one and at least $30 million in year two from eliminating public-company costs, G&A efficiencies, and manufacturing and supply-chain optimization.

预计该交易将推动Repligen的营收增长、调整后利润率以及调整后每股收益，在第一年至少增加5美分，在第二年至少增加25美分。Repligen预计，通过消除上市公司成本、实现一般及行政费用效率提升以及优化制造和供应链，将在第一年产生至少2,000万美元的协同效应，在第二年产生至少3,000万美元的协同效应。

While this combination is expected to generate important cross-selling opportunities, Repligen’s financial expectations only assume modest revenue synergies leaving the potential for future upside. The cash component of the merger consideration will be funded with cash on hand. Repligen’s balance sheet is expected to remain healthy with greater than $300 million of pro forma cash and cash equivalents, preserving optionality for additional M&A and other investment opportunities..

尽管预计该组合将产生重要的交叉销售机会，但Repligen的财务预期仅假设了适度的收入协同效应，从而为未来的上行潜力留下了空间。合并对价中的现金部分将以手头现金支付。预计Repligen的资产负债表将保持稳健，备考现金及现金等价物超过3亿美元，从而为额外的并购及其他投资机会保留灵活性。

Transaction Terms

交易条款

BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share. This represents an implied premium of 24% to 90-day volume-weighted average price (VWAP) for the period ended July 21, 2026.

BioLife 的股东将获得每股 11.25 美元的现金以及 0.1442 股 Repligen 普通股，相当于每股总价值为 31.00 美元。这代表相对于截至 2026 年 7 月 21 日的 90 天成交量加权平均价（VWAP）有 24% 的隐含溢价。

The Transaction is expected to close in the fourth quarter of 2026, subject to customary regulatory approvals, approval by BioLife stockholders, and the satisfaction of other customary closing conditions set forth in the merger agreement.

预计该交易将于2026年第四季度完成，但须以取得惯例监管批准、BioLife股东批准以及满足合并协议中规定的其他惯例交割条件为前提。

Preliminary & Unaudited Second Quarter 2026 Results

2026年第二季度初步且未经审计的业绩

Repligen expects preliminary second quarter revenue growth of approximately 12% as reported and 13% on an organic basis, both compared to the same period in 2025. In addition, Repligen expects to deliver strong year-over-year margin expansion. Repligen will report full second quarter results on July 28, 2026, before the market opens and will host a conference call at 8:00 a.m.

Repligen 预计第二季度初步营收同比增长约 12%（按报告基础计算）和 13%（按有机基础计算），均与 2025 年同期相比。此外，Repligen 预计将实现强劲的同比利润率扩张。Repligen 将于 2026 年 7 月 28 日市场开盘前公布完整的第二季度业绩，并于上午 8:00 举行电话会议。

ET..

东部时间..

BioLife expects preliminary second quarter revenue of $28.5 million, an increase of 21% compared with $23.4 million for the second quarter of 2025.   BioLife plans to report its full second quarter 2026 financial results on August 6, 2026. Due to the pending acquisition, BioLife will not be hosting an earnings conference call.  .

BioLife预计第二季度初步营收为2,850万美元，较2025年第二季度的2,340万美元增长21%。BioLife计划于2026年8月6日公布2026年第二季度完整财务业绩。由于收购事宜尚未完成，BioLife将不举行财报电话会议。

These preliminary results are unaudited and subject to change pending completion of each company’s quarter-end financial close process. The preliminary unaudited results of BioLife for the second quarter 2026 reflect only the continuing operations of BioLife unless otherwise noted.

这些初步结果未经审计，且在各公司完成季度末财务结账流程之前可能会发生变化。除非另有说明，BioLife 2026年第二季度的初步未经审计结果仅反映其持续经营业务。

Conference Call and Webcast Access

电话会议和网络直播接入方式

Repligen will host a conference call and webcast today, July 22, 2026, at 8:30 a.m. ET, to discuss the acquisition. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 747529619. In addition, a webcast will be accessible via the .

Repligen 将于今天，2026年7月22日，美国东部时间上午8:30举行电话会议和网络直播，讨论此次收购事宜。国内拨打者可免费拨打 (833) 461-5787，国际拨打者可拨打 (585) 542-9983 接入电话会议。会议ID为：747529619。此外，网络直播可通过以下方式访问。

Investor Relations

投资者关系

section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the

公司网站的相应栏目。网络直播将在活动结束后的一段时间内提供存档回放。您可以在以下网址观看回放：

Investor Relations

投资者关系

section of the Company’s website.

公司网站的一个部分。

Advisors

顾问

Perella Weinberg and Goldman Sachs & Co. LLC are serving as financial advisors and Goodwin Procter is serving as legal counsel to Repligen. Centerview Partners, LLC is serving as financial advisor and K&L Gates LLP is serving as legal counsel to BioLife.

佩雷拉·温伯格和高盛有限责任公司担任Repligen的财务顾问，古德温·普罗克特律师事务所担任其法律顾问。森特维尤伙伴有限责任公司担任BioLife的财务顾问，K&L Gates律师事务所担任其法律顾问。

About Repligen Corporation

关于Repligen公司

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are

Repligen Corporation 是一家全球性的生命科学公司，致力于开发并商业化高度创新的生物工艺技术及相关系统，以提高生物药生产流程的效率。我们是

“inspiring advances in bioprocessing”

“生物加工领域的鼓舞人心的进展”

for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

服务于我们所服务的客户；主要是全球生物制药药物开发商和合同开发与制造组织（CDMO）。我们的重点领域包括过滤与流体管理、色谱技术、过程分析以及蛋白质。公司总部位于马萨诸塞州沃尔瑟姆，大多数制造基地位于美国，此外在爱沙尼亚、德国、爱尔兰、荷兰和瑞典设有其他重要基地。

For more information about the Company see our website at .

有关本公司的更多信息，请访问我们的网站。

www.repligen.com

www.repligen.com

, and follow us on

，并在 上关注我们

LinkedIn

领英

.

。

About BioLife Solutions

关于 BioLife Solutions

BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution.

BioLife Solutions 是细胞和基因疗法（CGT）及更广泛生物制药市场生物生产产品和服务的领先开发商和供应商。我们的专业知识通过提供在采集、开发、储存和分销过程中维持生物材料健康和功能的解决方案，促进新疗法的商业化。

For more information, please visit .

更多信息，请访问。

www.biolifesolutions.com

www.biolifesolutions.com

or follow BioLife on

或在以下平台关注 BioLife

LinkedIn

领英

and

和

X

X

.

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

Statements included in this press release, which are not historical in nature or do not relate to current facts, are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provisions of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

本新闻稿中包含的非历史性质或与当前事实无关的陈述，旨在构成并在此被认定为前瞻性陈述，以符合联邦证券法律（包括《证券法》第27A条和经修订的《1934年证券交易法》（以下简称“《交易法》”）第21E条）中的安全港条款。

Forward-looking statements are based on, among other things, Repligen management’s and BioLife management’s beliefs, assumptions, current expectations, estimates and projections about the economy and Repligen and BioLife, as applicable, and the industries in which Repligen and BioLife operate. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements..

前瞻性陈述基于（其中包括）Repligen 管理层和 BioLife 管理层的信念、假设、当前预期、估计和预测，涉及经济状况以及 Repligen 和 BioLife（视情况而定）及其所处行业的情况。“可能”、“大约”、“继续”、“应该”、“预期”、“预测”、“ anticipate ”、“很可能”、“展望”、“期待”、“相信”、“将”、“打算”、“估计”、“战略”、“计划”、“可以”、“潜在”、“可能”等词语及其变体和类似表述旨在识别此类前瞻性陈述。

Forward-looking statements include statements regarding, among other things, the expected benefits of the Transaction and Repligen’s ability to recognize the benefits of the Transaction; the anticipated timing of the closing of the Transaction; the anticipated financial impact of the Transaction on Repligen and the belief that this is a financially compelling transaction and accretive in the near-term; expectations for Repligen’s performance following the Transaction, including future financial and operating results; beliefs that the Transaction will accelerate profitable growth; beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader; anticipated synergies; beliefs about the drivers for future growth following the Transaction, including with respect to the pipeline and regulatory matters; the expected impact on customers and revenue opportunities; Repligen’s second quarter results, including revenue growth and expectations for strong margin expansion and Repligen’s plans, objectives, expectations, intentions, growth strategies and other statements that are not historical facts.

前瞻性陈述包括关于以下内容的陈述：交易预期带来的益处以及Repligen实现这些益处的能力；预计的交易完成时间；交易对Repligen的预期财务影响，以及认为该交易在财务上具有吸引力并将在短期内增厚收益的看法；交易完成后Repligen的表现预期，包括未来的财务和运营结果；相信交易将加速盈利增长；对细胞治疗行业（包括其增长）的看法和预期，以及BioLife作为高度差异化的细胞处理工具领导者的地位；预期的协同效应；对交易后未来增长驱动因素的看法，包括与产品管线和监管事项相关的因素；对客户和收入机会的预期影响；Repligen第二季度的业绩，包括收入增长、对利润率大幅扩张的预期，以及Repligen的计划、目标、预期、意图、增长战略和其他非历史事实的陈述。

Repligen and BioLife caution readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results.

Repligen 和 BioLife 提醒读者，前瞻性陈述涉及某些风险和不确定性，这些风险和不确定性在发生的时间、范围、可能性和程度等方面难以预测，可能导致实际结果与预期结果存在重大差异。

Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the merger agreement; the outcome of any legal proceedings that may be.

此类风险和不确定性包括但不限于以下可能性：发生任何可能导致一方或双方有权终止合并协议的事件、变化或其他情况；任何可能发生的法律程序的结果。

Important Additional Information and Where to Find It

重要补充信息及查询方式

In connection with the Transaction, Repligen will file with the SEC a registration statement on Form S-4 (the “registration statement”), which will contain a proxy statement of BioLife and a prospectus of Repligen (the “proxy statement/prospectus”), and each of Repligen and BioLife may file with the SEC other relevant documents regarding the Transaction.

就本次交易而言，Repligen 公司将向美国证券交易委员会（SEC）提交一份 S-4 表格注册声明（“注册声明”），其中将包含 BioLife 公司的委托书声明和 Repligen 公司的招股说明书（合称“委托书声明/招股说明书”），且 Repligen 公司和 BioLife 公司均可能向美国证券交易委员会提交与本次交易相关的其他文件。

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY REPLIGEN AND BIOLIFE, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REPLIGEN, BIOLIFE AND THE TRANSACTION.

敦促投资者和证券持有人仔细阅读注册声明和代理声明/招股说明书的全文，以及Repligen和BioLife向美国证券交易委员会（SEC）提交的任何其他相关文件，并在这些文件的任何修订或补充材料发布时予以阅读，因为这些文件将包含有关Repligen、BioLife及本次交易的重要信息。

When final, a definitive copy of the proxy statement/prospectus will be mailed to BioLife stockholders. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus, as well as other filings containing information about Repligen and BioLife, free of charge from Repligen or BioLife or from the SEC’s website when they are filed.

最终定稿后，代理声明/招股说明书的正式副本将邮寄给 BioLife 的股东。投资者和证券持有人可以在 Repligen 或 BioLife 向美国证券交易委员会（SEC）提交文件时，从 Repligen、BioLife 或 SEC 网站免费获取注册声明、代理声明/招股说明书以及包含有关 Repligen 和 BioLife 信息的其他备案文件。

The documents filed by Repligen with the SEC may be obtained free of charge at Repligen’s website, at www.repligen.com, or by requesting them by mail at Repligen Corporation, 41 Seyon Street Building 1, Suite 100 Waltham, Massachusetts 02453, Attention: Corporate Secretary. The documents filed by BioLife with the SEC may be obtained free of charge at BioLife’s website, at www.

Repligen 向美国证券交易委员会（SEC）提交的文件可免费获取，途径包括访问 Repligen 网站（www.repligen.com），或通过邮寄方式向 Repligen Corporation 索取，地址为：41 Seyon Street Building 1, Suite 100, Waltham, Massachusetts 02453，收件人：公司秘书。BioLife 向美国证券交易委员会（SEC）提交的文件也可免费获取，途径包括访问 BioLife 网站（www.

biolifesolutions.com, or by requesting them by mail at BioLife Solutions, Inc., 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021, Attention: Corporate Secretary. The information included on Repligen’s and BioLife’s websites is not incorporated by reference into this press .

biolifesolutions.com，或通过邮寄方式向 BioLife Solutions, Inc. 索取，地址为：3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021，收件人：公司秘书。Repligen 和 BioLife 网站上包含的信息并未通过引用纳入本新闻稿。

Participants in the Solicitation

招标参与者

Repligen and BioLife and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of BioLife in respect of the Transaction. Information about Repligen’s directors and executive officers is available in Repligen’s proxy statement, dated April 2, 2026, for its 2026 Annual Meeting of Stockholders, and other documents filed by Repligen with the SEC.

Repligen、BioLife 以及它们各自的某些董事和高级管理人员可能被视为就本次交易向 BioLife 股东征集代理投票权的参与者。有关 Repligen 董事和高级管理人员的信息可在 Repligen 于 2026 年 4 月 2 日发布的关于其 2026 年度股东大会的代理声明，以及 Repligen 向美国证券交易委员会（SEC）提交的其他文件中查阅。

Information about BioLife’s directors and executive officers is available in BioLife’s proxy statement, dated July 8, 2025, for its 2025 Annual Meeting of Stockholders, and other documents filed by BioLife with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the Transaction when they become available.

有关BioLife董事及高级管理人员的信息，请参阅BioLife为其2025年年度股东大会发布的、日期为2025年7月8日的代理声明，以及BioLife向美国证券交易委员会（SEC）提交的其他文件。根据SEC规则可能被视为代理权征集参与者的相关人员信息，以及其通过证券持有或其他方式拥有的直接和间接权益的描述，将载于届时将向SEC提交的与本次交易相关的代理声明/招股说明书及其他相关材料中。

Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Repligen or BioLife as indicated above..

投资者在作出任何投票或投资决策之前，应在代理声明/招股说明书发布时仔细阅读。您可以按照上述指示从 Repligen 或 BioLife 免费获取这些文件的副本。

No Offer or Solicitation

无要约或招揽

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本新闻稿无意构成也不应被视为出售任何证券的要约或购买任何证券的要约邀请，且在根据任何此类司法管辖区的证券法进行注册或资格认定之前，若此类要约、邀请或销售在该司法管辖区属违法，则不得在该司法管辖区进行任何证券销售。

No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act..

除非通过符合《证券法》第10条要求的招股说明书，否则不得进行任何证券发行。

Non-GAAP Measures of Financial Performance

非公认会计准则财务绩效指标

This press release includes certain “non-GAAP measures.” Please refer to the Company’s “Non-GAAP Measures of Financial Performance” included within the Company’s current and historical filings on Forms 8-K for more information on the use of non-GAAP measures by the Company.

本新闻稿包含某些“非公认会计准则（non-GAAP）指标”。有关公司使用非公认会计准则指标的更多信息，请参阅公司在8-K表格的当前及历史备案文件中列载的“财务业绩的非公认会计准则指标”部分。

Repligen Preliminary Reconciliation of Total Revenue (GAAP) Growth to Organic Revenue Growth (Non-GAAP)

Repligen 总收入（GAAP）增长与有机收入增长（非 GAAP）的初步调节表

Q2 - 26

2026年第二季度

TOTAL REPORTED REVENUE (GAAP) GROWTH

报告总收入（GAAP）增长

12%

12%

Acquisition and divestiture revenue

收购与剥离收入

1%

百分之一

Currency exchange

货币兑换

0%

0%

ORGANIC REVENUE GROWTH (NON-GAAP)

有机收入增长（非公认会计准则）

13%

13%

Repligen

雷普利根

Investor Relations Contact:

投资者关系联系人：

Jacob Johnson

雅各布·约翰逊

VP, Investor Relations

投资者关系副总裁

781-419-0204

781-419-0204

investors@repligen.com

investors@repligen.com

BioLife Media & Investor Relations Contact:

BioLife 媒体与投资者关系联系人：

At the Company

在公司

Troy Wichterman

特洛伊·威希特曼

Chief Financial Officer

首席财务官

425.402.1400

425.402.1400

twichterman@biolifesolutions.com

twichterman@biolifesolutions.com

Investors

投资者

John Graziano

约翰·格拉齐亚诺

Investor Relations

投资者关系

jgraziano@biolifesolutions.com

jgraziano@biolifesolutions.com

Vivian Cervantes

维维安·塞万提斯

Alliance Advisors IR

联盟顾问投资者关系

973-873-7724

973-873-7724

vcervantes@allianceadvisors.com

vcervantes@allianceadvisors.com